| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quantitative Trait Loci | 15 | 2022 | 576 | 2.060 |
Why?
|
| Genome-Wide Association Study | 12 | 2022 | 1621 | 1.860 |
Why?
|
| Lung Neoplasms | 28 | 2014 | 2262 | 1.730 |
Why?
|
| Chromosome Mapping | 9 | 2022 | 1074 | 1.580 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2014 | 1075 | 1.420 |
Why?
|
| Animals, Outbred Strains | 2 | 2018 | 15 | 1.230 |
Why?
|
| Behavior, Animal | 6 | 2016 | 373 | 1.170 |
Why?
|
| Fear | 7 | 2015 | 78 | 1.080 |
Why?
|
| Alcoholism | 2 | 2022 | 172 | 0.810 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2010 | 2438 | 0.760 |
Why?
|
| Crosses, Genetic | 6 | 2014 | 171 | 0.680 |
Why?
|
| Organ Size | 2 | 2018 | 364 | 0.630 |
Why?
|
| Testis | 1 | 2018 | 152 | 0.620 |
Why?
|
| Genetics, Behavioral | 2 | 2013 | 22 | 0.570 |
Why?
|
| Genetic Markers | 2 | 2016 | 476 | 0.540 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1920 | 0.530 |
Why?
|
| Mice | 19 | 2022 | 11352 | 0.530 |
Why?
|
| Anxiety | 2 | 2014 | 287 | 0.510 |
Why?
|
| Motor Activity | 4 | 2015 | 327 | 0.500 |
Why?
|
| Genotype | 6 | 2018 | 1851 | 0.490 |
Why?
|
| Chromosomes | 1 | 2014 | 96 | 0.490 |
Why?
|
| Phenotype | 9 | 2022 | 2378 | 0.480 |
Why?
|
| Precision Medicine | 3 | 2014 | 395 | 0.460 |
Why?
|
| Animals | 25 | 2022 | 26582 | 0.450 |
Why?
|
| Carcinoma, Small Cell | 4 | 2014 | 134 | 0.440 |
Why?
|
| Alleles | 2 | 2017 | 1128 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2022 | 2357 | 0.420 |
Why?
|
| Models, Animal | 1 | 2013 | 263 | 0.420 |
Why?
|
| Methamphetamine | 2 | 2015 | 82 | 0.410 |
Why?
|
| Conditioning, Classical | 5 | 2015 | 35 | 0.410 |
Why?
|
| Body Weight | 2 | 2019 | 459 | 0.400 |
Why?
|
| Male | 38 | 2022 | 40965 | 0.390 |
Why?
|
| Neoplasm Staging | 13 | 2011 | 1939 | 0.380 |
Why?
|
| Carboplatin | 7 | 2010 | 286 | 0.380 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 532 | 0.370 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 394 | 0.340 |
Why?
|
| Early Detection of Cancer | 3 | 2013 | 394 | 0.340 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 2360 | 0.330 |
Why?
|
| Mice, Inbred DBA | 6 | 2014 | 148 | 0.320 |
Why?
|
| Quality of Life | 8 | 2008 | 1585 | 0.320 |
Why?
|
| Computational Biology | 3 | 2018 | 528 | 0.290 |
Why?
|
| Mice, Inbred Strains | 5 | 2014 | 307 | 0.290 |
Why?
|
| Health Status | 3 | 2008 | 360 | 0.280 |
Why?
|
| Female | 32 | 2019 | 44532 | 0.270 |
Why?
|
| Deoxycytidine | 3 | 2007 | 237 | 0.260 |
Why?
|
| Basolateral Nuclear Complex | 2 | 2015 | 3 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 9 | 2015 | 3092 | 0.250 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 449 | 0.240 |
Why?
|
| Humans | 44 | 2019 | 86643 | 0.240 |
Why?
|
| Databases, Genetic | 2 | 2017 | 260 | 0.230 |
Why?
|
| Survival Analysis | 9 | 2010 | 1538 | 0.220 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2014 | 98 | 0.220 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 178 | 0.210 |
Why?
|
| Pedigree | 2 | 2014 | 966 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 266 | 0.210 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 1169 | 0.200 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.200 |
Why?
|
| Central Nervous System Stimulants | 3 | 2015 | 216 | 0.200 |
Why?
|
| Neoplasms | 5 | 2014 | 2898 | 0.190 |
Why?
|
| Aged | 17 | 2019 | 18415 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 64 | 0.190 |
Why?
|
| Treatment Outcome | 14 | 2011 | 7993 | 0.190 |
Why?
|
| Quinazolines | 2 | 2006 | 220 | 0.190 |
Why?
|
| Nanotechnology | 1 | 2011 | 68 | 0.190 |
Why?
|
| Thinness | 1 | 2019 | 43 | 0.180 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2015 | 623 | 0.180 |
Why?
|
| Muscle Development | 1 | 2019 | 41 | 0.180 |
Why?
|
| Ethanol | 1 | 2022 | 249 | 0.180 |
Why?
|
| Body Composition | 1 | 2019 | 68 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2011 | 814 | 0.170 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 115 | 0.170 |
Why?
|
| Middle Aged | 19 | 2019 | 25028 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1376 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 179 | 0.170 |
Why?
|
| ErbB Receptors | 3 | 2011 | 485 | 0.170 |
Why?
|
| Aged, 80 and over | 10 | 2010 | 6509 | 0.160 |
Why?
|
| Glycoproteins | 1 | 2019 | 234 | 0.160 |
Why?
|
| Inbreeding | 3 | 2013 | 45 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2011 | 359 | 0.150 |
Why?
|
| Health Status Indicators | 1 | 2007 | 105 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2011 | 592 | 0.150 |
Why?
|
| Genetic Linkage | 1 | 2018 | 623 | 0.140 |
Why?
|
| Sulindac | 1 | 2006 | 10 | 0.140 |
Why?
|
| Electroshock | 2 | 2015 | 17 | 0.140 |
Why?
|
| Adult | 16 | 2019 | 25648 | 0.140 |
Why?
|
| Organoplatinum Compounds | 1 | 2006 | 94 | 0.140 |
Why?
|
| Dendritic Spines | 1 | 2015 | 15 | 0.140 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2015 | 19 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 268 | 0.140 |
Why?
|
| Camptothecin | 2 | 2007 | 189 | 0.140 |
Why?
|
| Dopaminergic Neurons | 1 | 2015 | 25 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 916 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2007 | 1169 | 0.130 |
Why?
|
| Spectrum Analysis | 2 | 2011 | 118 | 0.130 |
Why?
|
| Disease Progression | 5 | 2008 | 1531 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1464 | 0.130 |
Why?
|
| Genetics, Population | 1 | 2018 | 394 | 0.130 |
Why?
|
| Face | 1 | 2015 | 114 | 0.130 |
Why?
|
| Models, Genetic | 2 | 2013 | 926 | 0.130 |
Why?
|
| Paclitaxel | 6 | 2007 | 460 | 0.130 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 3640 | 0.130 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 68 | 0.120 |
Why?
|
| Codon, Nonsense | 1 | 2014 | 41 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2004 | 83 | 0.120 |
Why?
|
| Skull | 1 | 2015 | 249 | 0.120 |
Why?
|
| Hybridization, Genetic | 1 | 2014 | 104 | 0.120 |
Why?
|
| Breeding | 1 | 2013 | 39 | 0.120 |
Why?
|
| Zinc Fingers | 1 | 2013 | 56 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 68 | 0.120 |
Why?
|
| Neutropenia | 2 | 2009 | 215 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2014 | 3241 | 0.110 |
Why?
|
| Goals | 1 | 2013 | 67 | 0.110 |
Why?
|
| Melanoma | 2 | 2004 | 459 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 217 | 0.110 |
Why?
|
| Animals, Genetically Modified | 1 | 2013 | 181 | 0.110 |
Why?
|
| Mutation, Missense | 1 | 2014 | 276 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 486 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 124 | 0.110 |
Why?
|
| Receptors, Cannabinoid | 1 | 2012 | 4 | 0.110 |
Why?
|
| Prognosis | 7 | 2011 | 3679 | 0.110 |
Why?
|
| Mood Disorders | 1 | 2012 | 81 | 0.100 |
Why?
|
| Survival Rate | 6 | 2011 | 1863 | 0.100 |
Why?
|
| Protons | 1 | 2002 | 98 | 0.100 |
Why?
|
| Acoustic Stimulation | 1 | 2012 | 130 | 0.100 |
Why?
|
| Frontal Lobe | 1 | 2012 | 130 | 0.100 |
Why?
|
| Indazoles | 1 | 2011 | 68 | 0.100 |
Why?
|
| Adiposity | 1 | 2011 | 70 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2018 | 1351 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 114 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2012 | 255 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2011 | 256 | 0.100 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 318 | 0.100 |
Why?
|
| Cues | 1 | 2012 | 175 | 0.090 |
Why?
|
| Mouth Mucosa | 1 | 2010 | 67 | 0.090 |
Why?
|
| Skin Diseases, Infectious | 1 | 2009 | 13 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 297 | 0.090 |
Why?
|
| Rats | 2 | 2013 | 3990 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2006 | 1313 | 0.090 |
Why?
|
| Reward | 1 | 2011 | 181 | 0.090 |
Why?
|
| Combined Modality Therapy | 5 | 2004 | 1686 | 0.090 |
Why?
|
| Carcinogenicity Tests | 1 | 2009 | 5 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2010 | 930 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 546 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 927 | 0.090 |
Why?
|
| Sigmoidoscopy | 1 | 2009 | 36 | 0.090 |
Why?
|
| Pemetrexed | 1 | 2009 | 76 | 0.090 |
Why?
|
| Brain Neoplasms | 2 | 2002 | 763 | 0.090 |
Why?
|
| Glutamates | 1 | 2009 | 89 | 0.090 |
Why?
|
| Salvage Therapy | 3 | 2011 | 233 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 1204 | 0.080 |
Why?
|
| Guanine | 1 | 2009 | 208 | 0.080 |
Why?
|
| Fatigue | 1 | 2009 | 174 | 0.080 |
Why?
|
| Anemia | 1 | 2009 | 128 | 0.080 |
Why?
|
| Carcinoma | 1 | 2001 | 436 | 0.080 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 183 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2009 | 281 | 0.080 |
Why?
|
| Palliative Care | 1 | 1999 | 257 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2011 | 413 | 0.070 |
Why?
|
| Adenoma | 1 | 2009 | 235 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 1208 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 427 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 860 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2008 | 468 | 0.070 |
Why?
|
| Proteins | 1 | 2012 | 777 | 0.070 |
Why?
|
| Skin | 1 | 2009 | 554 | 0.070 |
Why?
|
| Brain | 1 | 2016 | 2216 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2008 | 751 | 0.070 |
Why?
|
| DNA, Neoplasm | 1 | 2006 | 265 | 0.060 |
Why?
|
| Mutation | 3 | 2011 | 3968 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2009 | 556 | 0.060 |
Why?
|
| Neurons | 1 | 2013 | 1546 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 1076 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2005 | 138 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2015 | 1981 | 0.060 |
Why?
|
| Breath Tests | 1 | 2013 | 55 | 0.060 |
Why?
|
| Taxoids | 2 | 2008 | 129 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2011 | 2261 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2005 | 329 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2007 | 865 | 0.050 |
Why?
|
| Peptide Synthases | 1 | 2022 | 12 | 0.050 |
Why?
|
| Age Factors | 3 | 2012 | 1851 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 589 | 0.050 |
Why?
|
| Sex Factors | 2 | 2014 | 1054 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.050 |
Why?
|
| Genes, ras | 1 | 2011 | 96 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2705 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2008 | 4213 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 70 | 0.050 |
Why?
|
| Remission Induction | 2 | 2004 | 722 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 128 | 0.050 |
Why?
|
| Prevalence | 2 | 2009 | 1239 | 0.050 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 159 | 0.050 |
Why?
|
| Cetuximab | 1 | 2010 | 113 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 199 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2005 | 678 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2008 | 31 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2004 | 292 | 0.040 |
Why?
|
| Psychological Tests | 1 | 2007 | 91 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2008 | 227 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2015 | 5 | 0.030 |
Why?
|
| Risk | 1 | 2008 | 674 | 0.030 |
Why?
|
| Avoidance Learning | 1 | 2015 | 16 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2009 | 8489 | 0.030 |
Why?
|
| Time Factors | 2 | 2006 | 5210 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2006 | 270 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 199 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2015 | 229 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1805 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 691 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2007 | 839 | 0.030 |
Why?
|
| Lod Score | 1 | 2014 | 152 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2014 | 36 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 222 | 0.030 |
Why?
|
| Vomiting | 1 | 2006 | 193 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 429 | 0.030 |
Why?
|
| Hindlimb | 1 | 2014 | 89 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2004 | 334 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 302 | 0.030 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2013 | 5 | 0.030 |
Why?
|
| Receptors, Mineralocorticoid | 1 | 2013 | 12 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2013 | 44 | 0.030 |
Why?
|
| Corticosterone | 1 | 2013 | 35 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1753 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 1 | 2013 | 64 | 0.030 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2013 | 81 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2601 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 2271 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 332 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 394 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2232 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 11 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 677 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1801 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1961 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 999 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2012 | 44 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2001 | 36 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2001 | 59 | 0.030 |
Why?
|
| Species Specificity | 1 | 2013 | 678 | 0.030 |
Why?
|
| International Agencies | 1 | 2011 | 34 | 0.030 |
Why?
|
| Craniotomy | 1 | 2001 | 88 | 0.020 |
Why?
|
| Genome | 1 | 2014 | 372 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2012 | 351 | 0.020 |
Why?
|
| Locomotion | 1 | 2012 | 131 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1219 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 153 | 0.020 |
Why?
|
| Skin Diseases, Viral | 1 | 2009 | 3 | 0.020 |
Why?
|
| Dermatomycoses | 1 | 2009 | 8 | 0.020 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2009 | 8 | 0.020 |
Why?
|
| Leukopenia | 1 | 2009 | 65 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 684 | 0.020 |
Why?
|
| Duodenal Neoplasms | 1 | 2009 | 19 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2501 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 96 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 119 | 0.020 |
Why?
|
| Duodenum | 1 | 2009 | 100 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 5976 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2009 | 172 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 1056 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2001 | 272 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 8981 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 2062 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 196 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2001 | 469 | 0.020 |
Why?
|
| Vinblastine | 1 | 2007 | 108 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 247 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1999 | 328 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2007 | 94 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3030 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 1924 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 609 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1565 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2012 | 2379 | 0.020 |
Why?
|
| Mass Screening | 1 | 2010 | 618 | 0.020 |
Why?
|
| Biopsy | 1 | 2009 | 1163 | 0.020 |
Why?
|
| Colon | 1 | 2009 | 496 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1991 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 3046 | 0.020 |
Why?
|
| United States | 1 | 2008 | 6672 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 3612 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 348 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 188 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2004 | 229 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2009 | 534 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 797 | 0.020 |
Why?
|
| Exons | 1 | 2006 | 450 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 879 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 468 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2004 | 196 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 977 | 0.010 |
Why?
|
| Child | 1 | 2012 | 6927 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 2903 | 0.010 |
Why?
|